SPRINGWORKS THERAPEUTICS, INC. [FORM OF] DIRECTOR INDEMNIFICATION AGREEMENTDirector Indemnification Agreement • August 16th, 2019 • SpringWorks Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This Indemnification Agreement (“Agreement”) is made as of [________] by and between SpringWorks Therapeutics, Inc., a Delaware corporation (the “Company”), and [Director] (“Indemnitee”).
SPRINGWORKS THERAPEUTICS, INC. [FORM OF] OFFICER INDEMNIFICATION AGREEMENTOfficer Indemnification Agreement • August 16th, 2019 • SpringWorks Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This Indemnification Agreement (“Agreement”) is made as of [________________] by and between SpringWorks Therapeutics, Inc., a Delaware corporation (the “Company”), and [Officer] (“Indemnitee”).1
springworks therapeutics, INC. EMPLOYMENT AGREEMENTEmployment Agreement • August 16th, 2019 • SpringWorks Therapeutics, Inc. • Biological products, (no disgnostic substances) • Connecticut
This Employment Agreement (“Agreement”) is made as of [_____________], 2019, between SpringWorks Therapeutics, Inc., a Delaware corporation (the “Company”), and [____________] (the “Employee”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”).
AMENDED AND RESTATED LICENSE AGREEMENT by and among SpringWorks Subsidiary 2, Inc., Pfizer Inc., Pfizer Products Inc. and, solely for purposes of Article 11 and Sections 3.2 and 3.3 hereof, SpringWorks Therapeutics, Inc., as of July 31, 2019License Agreement • August 16th, 2019 • SpringWorks Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
THIS AMENDED AND RESTATED LICENSE AGREEMENT (“Agreement”) is made effective as of the 31ST day of July, 2019 (the “Amendment Effective Date”), by and among SpringWorks Subsidiary 2, Inc., a corporation organized and existing under the laws of Delaware with offices at 100 Washington Blvd., 5th Floor, Stamford, CT 06902 (“Licensee”), Pfizer Inc., a corporation organized and existing under the laws of Delaware with offices at 235 East 42nd Street, New York, NY 10017 (“Pfizer Inc.”), Pfizer Products Inc., a corporation organized and existing under the laws of Delaware with offices at 235 East 42nd Street, New York, NY 10017 (“PPI” and, collectively with Pfizer Inc., “Pfizer”) and , solely with respect to Article 11 and Sections 3.2 and 3.3, SpringWorks Therapeutics, Inc., a Delaware corporation (“SpringWorks”). Licensee and Pfizer may, from time-to-time, be individually referred to as a “Party” and collectively referred to as the “Parties”.
CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENTClinical Trial Collaboration and Supply Agreement • August 16th, 2019 • SpringWorks Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT (this “Agreement”), made as of 25 June, 2019 (the “Effective Date”), is by and between GlaxoSmithKline LLC, a Delaware limited liability company, having a place of business at 1250 South Collegeville Road, Collegeville, PA 19426 (“GSK”) and SpringWorks Therapeutics, Inc., a Delaware corporation, having a place of business at 100 Washington Blvd., 5th Floor, Stamford, CT 06902 (“SpringWorks”). SpringWorks and GSK are each referred to herein individually as a “Party” and collectively as the “Parties”.
ASSIGNMENT AND ASSUMPTION OF LEASEAssignment and Assumption of Lease • August 16th, 2019 • SpringWorks Therapeutics, Inc. • Biological products, (no disgnostic substances) • Connecticut
LEASE dated the 1st day of December, 2011, by and between TWO HARBOR POINT SQUARE, LLC (“Landlord”), a Delaware limited liability company with an office at 100 Washington Boulevard, Suite 200, Stamford, CT 06902; and STRUCTURED PORTFOLIO MANAGEMENT, L.L.C. (“Tenant”), a Delaware limited liability company with an office at 2187 Atlantic Street, 4th Floor, Stamford, CT 06902.
CLINICAL COLLABORATION AGREEMENTClinical Collaboration Agreement • August 16th, 2019 • SpringWorks Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Clinical Collaboration Agreement (this “Agreement”), made as of August 16, 2018 (the “Effective Date”), is by and between SpringWorks Subsidiary 3, PBC, a public benefit corporation organized under the laws of Delaware (“SpringWorks”), and BeiGene, Ltd., a corporation organized under the laws of the Cayman Islands having its principal address at Mourant Ozannes Corporate Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, Cayman Islands KY1-1108 (“BeiGene”). BeiGene and SpringWorks are each referred to herein as a “Party” and are collectively referred to as the “Parties”.
